Médicament Québec Funds Two Additional Structuring Activities in Vaccine Technologies
Montréal, QC, October 14, 2025 — Médicament Québec is proud to announce a $2.2 million investment to support two new structuring activities under its Innovations in Vaccine Technologies program, funded by the Government of Québec. These collaborative initiatives between academia and industry, led by renowned principal investigators, aim to develop innovative and sustainable platforms that will strengthen Québec’s vaccine ecosystem.
These activities stand out thanks to the sustained support of Médicament Québec. Following an initial evaluation, they were further refined in collaboration with researchers and members of the evaluation committee through an iterative process designed to integrate recommendations, enhance industrial relevance, and ensure the establishment of shared platforms adaptable to different fields of application. This process has helped consolidate more robust activities with the support of a network mobilized toward their success—an added value that illustrates the Médicament Québec difference.
The financed activities are:
- Denis Leclerc, Full Professor, Department of Microbiology, Infectious Diseases and Immunology, Université Laval, and Infectious and Immune Diseases Axis, CHU de Québec–Université Laval Research Center
VaxSynergy — Unleashing innovation in vaccine development through a collaborative ecosystem – $1.5M in funding
This activity will establish an integrated platform bringing together multiple academic and industrial expertise to accelerate the development of subunit vaccines and novel adjuvants, from discovery through to clinical applications. - Maryam Tabrizian, Full Professor, Department of Biomedical Engineering, McGill University
Establishing a platform to innovate therapeutic vaccines using immunomodulatory nanoparticles derived from bacterial lipids against cancer –$0.8M in funding
This activity aims to create a next-generation technological platform using hybrid lipid nanoparticles to develop RNA-based therapeutic vaccines against metastatic cancer.
“We are proud to see the emergence of a total of six promising structuring activities in vaccine technologies, which completes a portfolio of 19 initiatives supported by Médicament Québec across small molecules, RNA, and vaccines. Together, these activities are building a stronger, more connected, and better-structured ecosystem for drug development in Québec,” emphasizes Arianne Trudeau, Executive Director, Médicament Québec.
“The Government of Québec is proud to support Médicament Québec’s Innovations in Vaccine Technologies program and once again witness the positive impact it generates. We firmly believe that collaboration within the life sciences ecosystem is the key to making Québec increasingly autonomous and innovative in drug development,” said Christine Fréchette, Minister of Economy, Innovation and Energy.
Click here to learn more about the funded projects.
-30-
Media Contact
Arianne Trudeau
Executive Director
Médicament Québec
arianne.trudeau@umontreal.ca
About Médicament Québec
Médicament Québec, an initiative funded by the Government of Québec, brings together research and teaching institutions as well as companies around a shared mission. Its goal is to increase Québec’s and Canada’s autonomy and dynamism in bioinnovation and biomanufacturing. Médicament Québec supports structuring and collaborative academic activities to strengthen local drug supply chains.
Comments are closed.